Ann Oncol 2022 04 10;33(4):416-425. Epub 2022 Jan 10.
Medical Oncology Department, Vall d'Hebron University Hospital and Institute of Oncology, Barcelona, Spain; Medical Oncology Department, IOB-Quiron, UVic-UCC, Barcelona, Spain.
Background: Tusamitamab ravtansine (SAR408701) is an antibody-drug conjugate composed of a humanized monoclonal antibody that binds carcinoembryonic antigen-related cell adhesion molecule-5 (CEACAM5) and a cytotoxic maytansinoid that selectively targets CEACAM5-expressing tumor cells. In this phase I dose-escalation study, we evaluated the safety, pharmacokinetics, and preliminary antitumor activity of tusamitamab ravtansine in patients with solid tumors.
Patients And Methods: Eligible patients were aged ≥18 years, had locally advanced/metastatic solid tumors that expressed or were likely to express CEACAM5, and had an Eastern Cooperative Oncology Group Performance Status of 0 or 1. Read More